

# 2019 CMR International Pharmaceutical R&D Factbook

August 2019

## CMR Factbook 2019- Pharma innovation in 2019: Staying ahead in the pharma market

Quickly see who's innovating in what space across pharma with the CMR International 2019 Pharmaceutical R&D Factbook, the definitive up-to-date business planning tool for decision makers in R&D, corporate finance, business strategy, marketing, clinical operations or corporate communications.

- When planning for years ahead, you want to know:
- How much is the industry predicted to spend on R&D over the next 3 years?
- How much annual revenue is the industry reinvesting into R&D?
- How many blockbusters are set to lose patent exclusivity over the next 3 years?
- Which therapeutic areas have seen positive growth in pipeline volume over recent years?
- Which therapeutic area is absorbing the majority of investment?
- How is patient recruitment shifting across the industry?

The CMR International Pharmaceutical R&D Factbook can provide you with answers to these questions and much more. CMR International, a Clarivate Analytics business, has gathered authoritative, robust industry metrics for every stage of pharmaceutical development. We turn this data into insightful, actionable knowledge. Metrics collected through CMR International can be incorporated into plans that steer strategy for individual companies and the industry as a whole.

## How the 2019 CMR International Pharma R&D Factbook can help your R&D Programs:

- Gain an in-depth understanding of industry dynamics and trends

- Determine how your organisation performs against the market as a whole
- Gauge your productivity relative to your competitors
- Recognize the key difference between individual therapeutic areas
- Appreciate the consequences of adopting different R&D strategies
- Set internal performance targets that will motivate and challenge your businesses

## Fully interactive charts and data

- Available as a "rich-data" Microsoft® Powerpoint® file, the slides present our results in a clear, easily understood format, perfect for presentation. Each slide is accompanied by a succinct explanation of the methodology used and the definitions applied.
- Includes over 75 robust charts, tables and graphs which are exportable to other applications. Simply copy/paste the graphics or slides into your own presentation.
- Each interactive chart or graph enables you to drill down to the underlying data with the click of a mouse, and analyse the figures behind the trend.

## Unlimited User Access

- The rich-data enterprise Powerpoint is accessible to unlimited users within your organisation.
- The file may be installed on a company network/intranet or distributed openly to any employee in your organisation.

# List of Figures

## Chapter 1. Overview

1. Summary of R&D Statistics for 2018
2. Global R&D expenditure, development times, global pharmaceutical sales and new molecular entity output 2008-2018
3. Global pharmaceutical R&D expenditure and annual changes in R&D expenditure 2008-2022p
4. Global pharmaceutical sales and annual changes in pharmaceutical sales 2008-2022p
5. Total R&D expenditure: sales ratio in 2018 by company size (max/median/min)
6. Number of new molecular entities and new active substances first launched onto the world market 2009-2018
7. Number of new molecular entities first launched onto the world market 2009-2018 by company size
8. Breakdown of total sales in 2018 by top 3 products and products launched in the previous 5 years
6. Changes in the number of lead projects in each development phase between 2014 and 2018 by active substance origin
7. Number of projects terminated in Phase III between 2013-2018

## Chapter 4. Success Rates

1. Probability of success to market for active substances
2. Probability of success to market from key milestones: changes over time
3. Probability of success to market by origin
4. Predicted number of active substances required at each stage to achieve one marketed active substance

## Chapter 5. Cycle Times

1. R&D key milestones
2. Development time for new molecular entities first launched onto the world market 2009-2018
3. Trend in actual clinical development time for lead projects submitted 2009-2017
4. Composite median interval duration for lead projects 2013-2017
5. Indexed trend in median interval durations for lead projects between 2009-2017

## Chapter 2. R&D Resources

1. Proportion of total R&D expenditure in 2018 by function
2. Proportion of total FTEs in 2018 by function
3. Proportion of total R&D expenditure on alliances or joint ventures by stage of R&D in 2018
4. Number of drug commercialization / licensing deals between 2014-2018
5. Proportion of total R&D expenditure in 2018 by phase of R&D
6. Proportion of total FTEs in 2018 allocated to each phase of R&D
7. Allocation of R&D expenditure between new development and line extension projects in 2017 and 2018
8. Allocation of R&D expenditure between internal and external spend by company size in 2018

## Chapter 6. Regional Comparisons

1. Regional distribution of total R&D expenditure in 2018
2. Region of first launch for new molecular entities 2009-2018
3. Proportional change of enrolled patients in each geographical region between 2011 and 2017
4. Median approval times for new active substances approved for three major regulatory agencies between 2008-2018
5. Regulatory approval times from date of submission to approval for new active substances approved between 2012-2016
6. Time between first world approval and submission in emerging market countries for new active substances approved between 2012-2016
7. Number of expedited and standard new active substance approvals 2007-2012 compared with 2013-2018
8. Median time in roll out to emerging market countries for new active substances approved between 2012-2016

## Chapter 3. R&D Pipeline Volume

1. Summary of R&D pipeline volume statistics for 2018
2. Trend in mean number of active substances developed for first launch between 2014-2018
3. Indexed trend in number of active substances entering each phase of development 2013-2018
4. Number of projects achieving key milestones between 2014-2018 by project type
5. Number of lead, parallel and line extension projects entering each phase of development between 2014-2018

# List of Figures

## Chapter 7. Therapeutic Area Focus

1. Total R&D expenditure in 2018 by therapeutic area
2. Total R&D expenditure in 2018 by therapeutic area by phase
3. Proportion of first new molecular entity launches in 2018 by therapeutic area
4. Change in number of lead projects in development for first launch between 2016-2018 by therapeutic area
5. Therapeutic area diversification between 2016-2018 by company size
6. Probability of success to market by therapeutic area (1) CMR success rates methodology
7. Probability of success to market by therapeutic area (2) CMR success rates methodology
8. Composite median interval durations for lead and parallel projects between 2013-2017 by therapeutic area
9. Median approval times for new active substances between 2013-2018 by therapeutic area

## Chapter 8. Biopharmaceutical Focus

1. Proportion of R&D expenditure in 2017 and 2018 by active substance type
2. Proportion of ethical pharmaceutical sales in 2018 by active substance type
3. Number of first NME launches between 2008-2018 by active substance type
4. Proportion of NBE active substances in development between 2014-2018 by company size
5. Proportion of licensed-in or acquired active substances in development in 2014 and 2018 by active substance type
6. Probability of success to market by active substance type
7. Composite median interval durations for lead projects between 2013-2017 by active substance type

## Chapter 9. Clinical Functions

1. Median total study duration in 2017
2. Clinical study median interval durations by study phase in 2017
3. Comparisons of the change in clinical study median interval durations between 2013 and 2017 by study phase

## Chapter 10. Patents

1. Number of pharmaceutical patent applications and granted patents for 5 major patent issuing authorities 2008-2018
2. Total and new compound WO, EP or US patent document filings 2010-2018
3. Most popular targets by number of 'new entrants' since 2016 for the industry
4. Most popular targets by number of 'new entrants' since 2016 for the 30 most innovative companies
5. Therapy area focus of the most popular emerging targets since 2016

## Chapter 11. Global Generics Market

1. Number of ANDA final approvals in each year between 2016-2018 by country of origin
2. Number of ANDA approvals for Indian generic companies between 2009-2018
3. Exposure of products to Paragraph IV challenges in US between 2012-2018
4. Total Paragraph IV challenges by country (count of single filing per group)
5. Number of products predicted to lose exclusivity in US between 2019-2025
6. Current experience of generic API manufacturers with regard to supplying the regulated markets
7. Number of European Certificates of Suitability (COS) granted between 2009-2018 by location of company headquarters
8. Number of US DMF granted each year between 2009-2018 by location of company headquarters
9. API Plants inspected by FDA in each year between 2010-2018 by location of company headquarters